Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-γ, reduces acute inflammation

European Journal of Pharmacology

Volumn 483, Issue 1, 2004, Pages 79-93

  Cuzzocrea, Salvatore ^a   Pisano, Barbara ^b   Dugo, Laura ^a   Ianaro, Angela ^b   Maffia, Pasquale ^b   Patel, Nimesh S A ^c   Di Paola, Rosanna ^a   Ialenti, Armando ^b   Genovese, Tiziana ^a   Chatterjee, Prabal K ^c   Di Rosa, Massimo ^b   Caputi, Achille P ^a   Thiemermann, Christoph ^c  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Cyclooxygenase 2; ICAM 1 (intercellular adhesion molecule 1); Inflammation, acute; iNOS (nitric oxide synthase inducible); PPAR (peroxisome proliferator activated receptor); Rosiglitazone

Indexed keywords

3 NITROTYROSINE; BISPHENOL A DIGLYCIDYLETHER; CARRAGEENAN; CYCLOOXYGENASE 2; INTERCELLULAR ADHESION MOLECULE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NITRIC OXIDE SYNTHASE; PADGEM PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RECEPTOR BLOCKING AGENT; ROSIGLITAZONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EXPERIMENTAL INFECTION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INFLAMMATORY INFILTRATE; MALE; NONHUMAN; PAW EDEMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PLEURA EMPYEMA; PRIORITY JOURNAL; RAT; RECEPTOR INTRINSIC ACTIVITY; TISSUE SECTION;

EID: 0347357686     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2003.10.056     Document Type: Article

References (48)

1. Bradford C. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
2. Butcher E.C. Specificity of leukocyte-endothelial interactions and diapedesis: physiologic and therapeutic implications of an active decision process. Res. Immunol. 144:1993;695-698.
3. Chatham W.W., Swaim R., Frohsin H. Jr., Heck L.W., Miller E.J., Blackburn W.D. Jr. Degradation of human articular cartilage by neutrophils in synovial fluid. Arthritis Rheum. 36:1993;51-58.
4. Chinetti G., Fruchart J.C., Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm. Res. 49:2000;497-505.
5. Corton J.C., Anderson S.P., Stauber A. Central role of peroxisome proliferator-activated receptors in the actions of peroxisome proliferators. Annu. Rev. Pharmacol. Toxicol. 40:2000;491-518.
6. Crofford L.J., Tan B., McCarthy C.J., Hla T. Involvement of nuclear factor kappa B in the regulation of cyclooxygenase-2 expression by interleukin-1 in rheumatoid synoviocytes. Arthritis Rheum. 40:1997;226-236.
7. Cuzzocrea S., Zingarelli B., Gilard E., Hake P., Salzman A.L., Szabó C. Protective effect of melatonin in carrageenan-induced models of local inflammation. J. Pineal Res. 23:1997;106-116.
8. Cuzzocrea S., Zingarelli B., Gilard E., Hake P., Salzman A.L., Szabó C. Anti-inflammatory effects of mercaptoethylguanidine, a combined inhibitor of nitric oxide synthase and peroxynitrite scavenger, in carrageenan-induced models of inflammation. Free Radic. Biol. Med. 24:1998;450-459.
9. Cuzzocrea S., Costantino G., Mazzon E., Caputi A.P. Beneficial effects of raxofelast (IRFI 016), a new hydrophilic vitamin e-like antioxidant, in carrageenan-induced pleurisy. Br. J. Pharmacol. 126:1999;407-414.
10. Cuzzocrea S., Mazzon E., Sautebin L., Dugo L., Serraino I., De Sarro A., Caputi A.P. Protective effects of Celecoxib on lung injury and red blood cells modification induced by carrageenan in the rat. Biochem. Pharmacol. 63:2002;785-795.
11. 2, ligands of the peroxisome proliferator-activated receptor-γ (PPAR-γ), reduce ischaemia/reperfusion injury of the gut. Br. J. Pharmacol. 148:2003;366-376.
12. Dawson J., Sedgwick A.D., Edwards J.C., Lees P. A comparative study of the cellular, exudative and histological responses to carrageenan, dextran and zymosan in the mouse. Int. J. Tissue React. 13:1999;171-185.
13. Delerive P., Fruchart J.C., Staels B. Peroxisome proliferator-activated receptors in inflammation control. J. Endocrinol. 169:2001;453-459.
14. Devchand P.R., Keller H., Peters J.M., Vazquez M., Gonzalez F.J., Wahli W. The PPARalpha-leukotriene B4 pathway to inflammation control. Nature. 384:1996;39-43.
15. Di Rosa M., Willoughby D.A. Screens for anti-inflammatory drugs. J. Pharm. Pharmacol. 23:1971;297-298.
16. Eiserich J.P., Cross C.E., Jones A.D. Formation of nitrating and chlorinating species by reaction of nitrite with hypochlorous acid. A novel mechanism for nitric oxide-mediated protein modification. J. Biol. Chem. 271:1996;191-199.
17. Escher P., Wahli W. Peroxisome proliferator-activated receptors: insight into multiple cellular functions. Mutat. Res. 448:2000;121-138.
18. Fahmi H., Di Battista J.A., Pelletier J.P., Mineau F., Ranger P., Martel-Pelletier J. Peroxisome proliferator-activated receptor gamma activators inhibit interleukin-1 beta-induced nitric oxide and matrix metalloproteinase 13 production in human chondrocytes. Arthritis Rheum. 44:2001;595-607.
19. Harada Y., Hatanaka K., Kawamura M., Saito M., Ogino M., Majima M., Ohno T., Yamamoto K., Taketani Y., Yamamoto S., Katori M. Role of Prostaglandin H synthase-2 in prostaglandin E2 formation in rat carrageenin-induced pleurisy. Prostaglandins. 51:1996;19-33.
20. Hill M.R., Clarke S., Rodgers K., Thornhill B., Peters J.M., Gonzalez F.J., Gimble J.M. Effect of peroxisome proliferator-activated receptor alpha activators on tumor necrosis factor expression in mice during endotoxemia. Infect. Immun. 67:1999;3488-3493.
21. Inoue S., Kawanishi S. Oxidative DNA damage induced by simultaneous generation of nitric oxide and superoxide. FEBS Lett. 371:1995;86-88.
22. Jiang C., Ting A.T., Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature. 391:1998;82-86.
23. Kadowaki T. Insights into insulin resistance and type 2 diabetes from knockout mouse models. J. Clin. Invest. 106:2000;1305-1307.
24. Karin M. The NF-kappa B activation pathway: its regulation and role in inflammation and cell survival. Cancer J. Sci. Am. 1:1998;S92-S99.
25. Lehmann J.M., Moore L.B., Smith-Oliver T.A., Wilkison W.O., Willson T.M., Kliewer S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPARγ). J. Biol. Chem. 270:1995;12953-12956.
26. Lehmann J.M., Lenhard J.M., Oliver B.B., Ringold G.M., Kliewer S.A. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem. 272:1997;3406-3410.
27. Masferrer J.L., Zweifel B.S., Manning P.T., Hauser S.D., Leahy K.M., Smith W.G., Isakson P.C., Seibert K. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc. Natl. Acad. Sci. U. S. A. 91:1994;3228-3232.
28. Mullane K.M., Kraemer R., Smith B. Myeloperoxidase activity as a quantitative assessment of neutrophil infiltration into ischemic myocardium. J. Pharmacol. Methods. 14:1985;157-167.
29. Nantel F., Denis D., Gordon R., Northey A., Cirino M., Metters K.M., Chan C.C. Distribution and regulation of cyclooxygenase-2 in carrageenan-induced inflammation. Br. J. Pharmacol. 128:1999;853-859.
30. Ohkawa H., Ohishi N., Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 92:1979;351-358.
31. Patel K.D., Zimmerman G.A., Prescott S.M., McEver R.P., McIntyre T.M. Oxygen radicals induce human endothelial cells to express GMP-140 and bind neutrophils. J. Cell Biol. 112:1991;749-759.
32. Ricote M., Li A.C., Willson T.M., Kelly J., Glass C.K. The peroxisome proliferator activated receptor-g is a negative regulator of macrophage activation. Nature. 391:1998;79-82.
33. Salvemini D., Wang Z.Q., Bourdon D.M., Stern M.K., Currie M.G., Manning P.T. Evidence of peroxynitrite involvement in the carrageenan-induced rat paw oedema. Eur. J. Pharmacol. 303:1996;217-220.
34. Salvemini D., Wang Z.Q., Stern M.K., Currie M.G., Misko T.P. Peroxynitrite decomposition catalysts: therapeutics for peroxynitrite-mediated pathology. Proc. Natl. Acad. Sci. U. S. A. 95:1998;2659-2663.
35. Staels B., Koenig W., Habib A. Activation of human aortic smooth-muscle cells is inhibited by PPAR alpha but not by PPARγ activators. Nature. 393:1998;790-793.
36. Szabó C., Lim L.H.K., Cuzzocrea S., Getting S.J., Zingarelli B., Flower R.J., Salzman A.L., Perretti M. Inhibition of poly (ADP-ribose) synthetase exerts anti-inflammatory effects and inhibits neutrophil recruitment. J. Exp. Med. 186:1997;1041-1049.
37. Szabó C., Viràg L., Cuzzocrea S., Scott G.S., Hake P., O'connor M., Zingarelli B., Ma Y., Hirsch R., Boiovin G.P., Salzman A.L., Kun E. Protection against peroxynitrite-induced fibroblast injury and arthritis development by inhibition of poly (ADP-Ribose) synthetase. Proc. Natl. Acad. Sci. U. S. A. 9:1998;3867-3872.
38. Taylor B.K., Dadia N., Yang C.B., Krishnan S., Badr M. Peroxisome proliferator-activated receptor agonists inhibit inflammatory edema and hyperalgesia. Inflammation. 26:2002;121-127.
39. Tomlinson A., Appleton I., Moore A.R., Gilroy D.W., Willis D., Mitchell J.A., Willoughby D.A. Cyclo-oxygenase and nitric oxide synthase isoforms in rat carrageenin-induced pleurisy. Br. J. Pharmacol. 113:1994;693-698.
40. Vamecq J., Latruffe N. Medical significance of peroxisome proliferator-activated receptors. Lancet. 354:1999;141-148.
41. Vane J. Towards a better aspirin. Nature. 367:1994;215-216.
42. Wei X.Q., Charles I.G., Smith A., Ure J., Feng G.J., Huang F.P., Xu D., Muller W., Moncada S., Liew F.Y. Altered immune responses in mice lacking inducible nitric oxide synthase. Nature. 375:1995;408-411.
43. Wertheimer S.J., Myers C.L., Wallace R.W., Parks T.P. Intercellular adhesion molecule-1 gene expression in human endothelial cells. J. Biol. Chem. 267:1992;12030-12035.
44. Willis D., Moore A.R., Frederick R., Willoughby D.A. Heme oxygenase: a novel target for the modulation of the inflammatory response. Nat. Med. 2:1996;87-90.
45. Willson T.M., Cobb J.E., Cowan D.J. The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones. J. Med. Chem. 39:1996;665-668.
46. Wright H.M., Clish C.B., Mikami T., Hauser S., Yanagi K., Hiramatsu R., Serhan C.N., Spiegelman B.M. A synthetic antagonist for the peroxisome proliferator-activated receptor gamma inhibits adipocyte differentiation. J. Biol. Chem. 275:2000;1873-1877.
47. Yamamoto K., Arakawa T., Ueda N., Yamamoto S. Transcriptional roles of nuclear factor kappa B and nuclear factor-interleukin-6 in the tumor necrosis factor-alpha-dependent induction of cyclooxygenase-2 in MC3T3-E1 cells. J. Biol. Chem. 270:1995;31315-31320.
48. Youssef J., Badr M. Peroxisome proliferator-activated receptors. From orphanage to fame in decade. Saudi Pharm. J. 9:2001;1-13.